Fosamax-Related Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Inquiry

The legacy of general health and science communication has long served to bridge complex biomedical concepts with public understanding, emphasizing prevention and informed decision-making. Within this tradition, discussions of medication safety and adverse effects have been framed in broad, accessible terms, often focusing on population-level risks and the importance of patient-provider dialogue. This heritage provides a foundation for examining how specific pharmaceutical exposures may intersect with individual health outcomes, particularly when long-term use is involved. Transitioning from this general context, a more focused inquiry emerges regarding bisphosphonate therapy, such as Fosamax, and its potential association with osteonecrosis of the jaw. While the general health discourse typically addresses medication risks in aggregate, occupational and environmental health perspectives demand scrutiny of exposure pathways that may amplify vulnerability. In particular, the concern shifts toward how sustained pharmacological exposure—whether through prescribed regimens or unintended occupational contact—could influence tissue-level responses. This pivot requires examining not only the biological plausibility of such associations but also the practical implications for those with prolonged exposure histories, including workers in healthcare or manufacturing settings where bisphosphonate compounds may be handled. The transition thus moves from broad health education to a targeted consideration of exposure risk, setting the stage for a more detailed exploration of causation without delving into mechanistic specifics.

Biological Plausibility: How Fosamax May Contribute to ONJ

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibition of bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a rare but serious adverse event: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure for more than eight weeks in the absence of radiation therapy to the jaws. The biological plausibility linking Fosamax to ONJ is supported by several mechanistic pathways. Bisphosphonates, including alendronate, accumulate in bone tissue and suppress osteoclast-mediated bone remodeling. The jawbone has a high rate of bone turnover due to constant mechanical stress from chewing and the presence of teeth, making it particularly susceptible to the effects of suppressed remodeling. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats have examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate therapy alters the mechanical and material properties of the jawbone, potentially predisposing it to necrosis.

Mechanistic Pathways and Risk Factors

The proposed mechanistic pathway involves several steps. First, bisphosphonates inhibit osteoclast activity, reducing bone resorption and turnover. This leads to accumulation of microdamage and decreased ability to repair bone. Second, the jawbone's high turnover rate and exposure to oral bacteria make it vulnerable to infection and impaired healing. Third, dental procedures such as tooth extraction create a portal for infection and further compromise blood supply. The combination of suppressed bone remodeling, microdamage accumulation, and infection can result in non-healing bone lesions characteristic of ONJ. Risk factors for developing ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Warning Adequacy

Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also identifies known risk factors and recommends that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may affect the perceived strength of the association. For affected patients, causation considerations include the presence of known risk factors, duration of bisphosphonate exposure, and temporal relationship between drug initiation and onset of ONJ. The biological plausibility is supported by mechanistic studies showing altered jawbone properties with bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077). However, ONJ can also occur spontaneously in patients not taking bisphosphonates, and the condition is multifactorial. Therefore, establishing causation in individual cases requires careful evaluation of all contributing factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility linking Fosamax to osteonecrosis of the jaw?

Fosamax (alendronate) suppresses osteoclast-mediated bone remodeling, leading to accumulation of microdamage and reduced repair capacity. The jawbone's high turnover rate and exposure to oral bacteria make it particularly vulnerable. Studies show altered mechanical and material properties of jawbone with bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077), supporting a plausible mechanism for ONJ development.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Duration of bisphosphonate exposure may increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improved after stopping, but some had recurrence upon rechallenge.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.